

## Stereocontrolled Synthesis of Calyculin A: Construction of the C(15)–C(25) Spiroketal Unit

Anthony G. M. Barrett,<sup>a</sup> Jeremy J. Edmunds,<sup>b</sup> Kiyoshi Horita<sup>a</sup> and Christopher J. Parkinson<sup>a</sup>

<sup>a</sup> Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, USA


<sup>b</sup> Department of Chemistry, Northwestern University, Evanston, Illinois 60208, USA

Two concise enantioselective syntheses of the C(15)–C(25) spiroketal unit of calyculin A, using derivatives of allyldiisopinocampheylborane efficiently to control 1,2- and 1,3-diol stereochemistries, are reported.


The calyculins are a group of marine natural products isolated from the sponge *Disocodermia calyx*.<sup>1</sup> Calyculin A **1** is a representative member of the series and the other calyculins differ from **1** by the presence of an additional methyl group at C-32 and/or by a change in the geometry of  $\Delta^2$  and/or  $\Delta^6$ . These structurally unusual substances are all noted for their potent activity in the starfish egg assay. All are very powerful inhibitors of phosphatase enzymes and are particularly effective against PP-1 and PP-2A phosphatases. For example,

calyculin A **1** is active against rabbit skeletal muscle type PP-2A phosphatases at 0.5–1.0 nmol dm<sup>-3</sup> concentrations. Additionally, **1** is 20–300 times more active than okadaic acid against various PP-1 enzymes. In contrast, calyculin A **1** does not inhibit various acid, alkaline, and protein tyrosine phosphatases even at 1  $\mu$ mol dm<sup>-3</sup> concentration. Calyculin A **1** also shows other activities. It is equipotent with phorbol esters and teleocidins in inflammation and tumour promotion tests.

In common with many other marine and terrestrial natural



**Scheme 1** Reagents and conditions: (a) **12**, THF, Et<sub>2</sub>O, -78 °C; NaBO<sub>3</sub>·4H<sub>2</sub>O, H<sub>2</sub>O; (b) Bu<sup>t</sup>Me<sub>2</sub>SiOSO<sub>2</sub>CF<sub>3</sub>, THF, 2,6-lutidine; (c) OsO<sub>4</sub> (catalytic), *N*-methylmorpholine *N*-oxide, Me<sub>2</sub>CO, H<sub>2</sub>O; (d) NaIO<sub>4</sub>, THF, H<sub>2</sub>O; (e) **13**, THF, Et<sub>2</sub>O, -78 °C; HOCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, NaH (catalytic); (f) KN(SiMe<sub>3</sub>)<sub>2</sub>, THF, DMF, *p*-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>Cl; (g) Bu<sub>4</sub>NF, THF; (h) Swern oxidation; (i) MeMgBr, THF; (j) LDA, THF, -78 °C, add **6**; TsOH, MeOH, 25 °C; (k) KBHBU<sub>3</sub>, THF, -78 to -10 °C; NaOH, H<sub>2</sub>O<sub>2</sub>. THF = tetrahydrofuran; DMF = dimethylformamide; LDA = lithium diisopropylamide; Ts = *p*-tolylsulfonyl; SEM = (2-trimethylsilyloxy)methyl.



**Scheme 2** Reagents and conditions: (a) R<sup>1</sup>Cl, Pr<sub>2</sub>N<sup>+</sup>Et, CH<sub>2</sub>Cl<sub>2</sub>; (b) LiAlH<sub>4</sub>, Et<sub>2</sub>O; (c) Swern oxidation; (d) Ph<sub>3</sub>P=CHCO<sub>2</sub>Me, CH<sub>2</sub>Cl<sub>2</sub>; (e) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>; (f) Sharpless epoxidation; (g) Red-Al, THF; (h) PPTS, Me<sub>2</sub>C(OMe)<sub>2</sub>, PhH; (i) Na, NH<sub>3</sub>, THF; (j) **9**, LDA, THF, -78 °C, add **17**; TsOH, MeOH, 25 °C (k) KBH<sub>4</sub>, THF, -78 to -10 °C; NaOH, H<sub>2</sub>O<sub>2</sub>; (l) Et<sub>3</sub>SiCl, Et<sub>3</sub>N, imidazole, CH<sub>2</sub>Cl<sub>2</sub>, -40 to -20 °C; (m) Bu<sup>t</sup>Me<sub>2</sub>SiOTf, Pr<sub>2</sub>N<sup>+</sup>Et, CH<sub>2</sub>Cl<sub>2</sub>; (n) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C; Me<sub>2</sub>S. DIBAL-H = diisobutylaluminium hydride; PPTS = pyridinium *p*-sulfonate; Tf = trifluoromethylsulfonyl.

products, calyculin A **1** contains a spiroketal unit<sup>2</sup> and a 2,4-disubstituted oxazole residue.<sup>3</sup> Recent studies by both Fusetani and Shioiri have established the absolute stereochemistry of calyculin A as structure **1**.<sup>4</sup> In addition, several groups have reported synthetic studies on various fragments of calyculin, and Evans has completed the synthesis of the entire carbon skeleton of the natural product.<sup>5</sup> However, to date, no completed total syntheses have been reported. We now first report<sup>6</sup> our own approaches to these important natural products. Retrosynthetically, we considered that calyculin A **1** should be available from the oxazole amide **2**, the cyanostannane **3**, and the spiroketal diene **4**.<sup>†</sup> In turn, it should be possible to construct the spiroketal unit **4** using an aldol reaction to establish the C(14)–C(15) bond. Herein, we describe two concise enantioselective syntheses of the C(15)–C(25) calyculin spiroketal residues **11** and **20**.

Brown has introduced various allyl derivatives of diisopinocampheylborane as versatile reagents for the stereoselective construction of homoallylic alcohols.<sup>7</sup> This most elegant masked aldol chemistry forms the cornerstone of the asymmetric synthesis in Schemes 1 and 2. Thus, reaction of aldehyde **5** with (–)-(Z)-crotonyldiisopinocampheylborane **12**, the reagent derived from (+)-α-pinene,<sup>7</sup> gave the corresponding homoallylic alcohol and this was readily transformed<sup>8,9</sup> into the protected aldehyde **6**.<sup>‡</sup> In this transformation, the *syn*-relative stereochemistry (>95%)<sup>§</sup> and the enantiomeric purity of the product (>95%)<sup>¶</sup> were both excellent.

The aldehyde **7** was smoothly converted into the protected *syn*-diol derivative **8** using, as a key step, addition of the (Z)-borane **13**. Again this process, which is a variation of

Brown's methodology,<sup>7,10</sup> efficiently controlled both relative (>95%)<sup>§</sup> and absolute (>95%)<sup>¶</sup> stereochemistry. Reagent **13**, which is readily available from (3,5-dioxaoct-7-en-1-yl)trimethylsilane *via* lithiation (Bu<sup>t</sup>Li, THF, -78 °C) and metathesis<sup>7</sup> with (+)-*B*-methoxydiisopinocampheylborane, should prove of general utility for the assembly of *syn*-1,2-diol arrays. The alcohol **8** was converted using three routine operations into the methyl ketone **9** (89%). Aldol coupling of ketone **9** and aldehyde **6** and acidification gave the spiroketal **10** as a mixture of stereoisomers. It is remarkable that these mild acidification reaction conditions resulted in cleavage of the usually robust<sup>8</sup> SEM protecting group, desilylation, and spirocyclization. Although the two epimers of **10** could be easily separated and authenticated, the mixture, on a larger scale, was oxidized and stereoselectively reduced using K-Selectride<sup>11</sup> to give only the required axial isomer **11**.

A second synthesis of the spiroketal unit of calyculin A was also undertaken. This provided additional material for the total synthesis and unequivocally established the structures in Scheme 1. Commercial methyl (*R*)-(+)-3-hydroxy-2-methylpropanoate **14** was converted into the aldehyde **17** *via* protection,<sup>8</sup> Swern oxidation,<sup>12</sup> and a Wittig homologation–Sharpless epoxidation sequence<sup>13</sup> as key processes. Aldol reaction of ketone **9** and aldehyde **17** gave, on acidification, the spiroketal **18**. Again, this substance was formed as a mixture of epimers. Swern oxidation gave the corresponding keto-aldehyde and this was smoothly reduced to provide the diol **19**. This substance was fully authenticated by an X-ray crystallographic study. || Additionally, spiroketals **11** and **19** were correlated by deprotection. Finally, selective protection<sup>8</sup> of diol **19** and ozonolysis<sup>14</sup> gave the C(15)–C(25) spiroketal unit **20**.

In conclusion, we have designed two concise methods for the elaboration of the spiroketal unit of calyculin A **1**. These reactions underscore the flexibility and power of diisopinocampheylborane derivatives in asymmetric synthesis. Further progress in the area is summarized in the accompanying communications.

<sup>†</sup> The synthesis was started before the determination of the absolute stereochemistry of the calyculins. Arbitrarily, the synthesis was directed towards the antipode of the natural product.

<sup>‡</sup> All new compounds were fully characterized by spectral data and microanalyses or HRMS.

<sup>§</sup> In each case the diastereoselectivity was estimated from the <sup>1</sup>H NMR spectrum.

<sup>¶</sup> In each case, enantiomeric purities were estimated *via* the preparation of the corresponding Mosher ester and <sup>1</sup>H NMR spectroscopy, see J. A. Dale, D. L. Dull and H. S. Mosher, *J. Org. Chem.*, 1969, **34**, 2543.

|| Details of the crystal structure of the diol **19** will be published elsewhere: M. A. Miller and O. P. Anderson, unpublished observations.

We thank the National Institutes of Health for support for this program (AI-20644), G. D. Searle & Company for unrestricted support and microanalyses, the Uehara Memorial Life Science Fund for a fellowship (to K.H.), and the Department of Chemistry, Northwestern University for all FAB and HRMS data.

Received, 13th May 1992; Com. 2/02478K

## References

- 1 S. Matsunaga, H. Fujiki, D. Sakata and N. Fusetani, *Tetrahedron*, 1991, **47**, 2999 and references therein.
- 2 F. Perron and K. F. Albizzati, *Chem. Rev.*, 1989, **89**, 1617.
- 3 J. R. Lewis, *Nat. Prod. Rep.*, 1988, 351.
- 4 S. Matsunaga and N. Fusetani, *Tetrahedron Lett.*, 1991, **32**, 5605; Y. Hamada, Y. Tanada, F. Yokokawa and T. Shioiri, *Tetrahedron Lett.*, 1991, **32**, 5983.
- 5 D. A. Evans and J. R. Gage, *Tetrahedron Lett.*, 1990, **31**, 6129; A. J. Duplantier, M. H. Nantz, J. C. Roberts, R. P. Short, P. Somfai and S. Masamune, *Tetrahedron Lett.*, 1989, **30**, 7357; Z. Zhao, G. R. Scarlato and R. W. Armstrong, *Tetrahedron Lett.*, 1991, **32**, 1609; A. B. Smith III, J. J.-W. Duan, K. G. Hull and B. A. Salvatore, *Tetrahedron Lett.*, 1991, **32**, 4855; A. B. Smith III, B. A. Salvatore, K. G. Hull and J. J.-W. Duan, *Tetrahedron Lett.*, 1991, **32**, 4859; R. W. Armstrong and J. A. DeMattei, *Tetrahedron Lett.*, 1991, **32**, 5749; A. M. P. Koskinen and J. Chen, *Tetrahedron Lett.*, 1991, **32**, 6977; O. Hara, Y. Hamada and T. Shioiri, *Synlett*, 1991, 283, 285; F. Yokokawa, Y. Hamada and T. Shioiri, *Synlett*, 1991, 149, 151, 153; D. A. Evans and J. R. Gage, *J. Org. Chem.*, 1992, **57**, 1958; D. A. Evans, J. R. Gage, J. L. Leighton and A. J. Kim, *J. Org. Chem.*, 1992, **57**, 1961; D. A. Evans, J. R. Gage and J. L. Leighton, *J. Org. Chem.*, 1992, **57**, 1964.
- 6 This work was presented at the 12th International Conference on Organic Synthesis, Cambridge, England, 23–25 July, 1991.
- 7 For example, see: U. S. Racherla and H. C. Brown, *J. Org. Chem.*, 1991, **56**, 401; P. K. Jadhav, K. S. Bhat, P. T. Perumal and H. C. Brown, *J. Org. Chem.*, 1986, **51**, 432; H. C. Brown and K. S. Bhat, *J. Am. Chem. Soc.*, 1986, **108**, 5919; H. C. Brown, R. S. Randad, K. S. Bhat, M. Zaidlewicz and U. S. Racherla, *J. Am. Chem. Soc.*, 1990, **112**, 2389; M. Srebnik and P. V. Ramachandran, *Aldrichim. Acta*, 1987, **20**, 9 and references therein.
- 8 T. W. Greene, *Protective Groups in Organic Synthesis*, Wiley, New York, 1981; T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic Synthesis*, 2nd edn., Wiley, New York, 1991; H. Kunz and H. Waldmann, 'Protecting Groups', in *Comprehensive Organic Synthesis*, B. M. Trost, I. Fleming and E. Winterfeldt, Pergamon Press, Oxford, 1991, vol. 6, pp. 631–701.
- 9 R. Pappo, D. S. Allen, R. U. Lemieux and W. S. Johnson, *J. Org. Chem.*, 1956, **21**, 478.
- 10 H. C. Brown, P. K. Jadhav and K. S. Bhat, *J. Am. Chem. Soc.*, 1988, **110**, 1535.
- 11 C. A. Brown, *J. Am. Chem. Soc.*, 1973, **95**, 4100.
- 12 A. J. Mancuso, D. S. Brownfain and D. Swern, *J. Org. Chem.*, 1979, **44**, 4148.
- 13 P. Ma, V. S. Martin, S. Masamune, K. B. Sharpless and S. M. Viti, *J. Org. Chem.*, 1982, **47**, 1378.
- 14 J. J. Pappas, W. P. Keaveney, E. Gancher and M. Berger, *Tetrahedron Lett.*, 1966, 4273.